The treatment of alk-d5f3 non-small cell lung cancer includes surgery, drug therapy, targeted therapy, radiation therapy, interventional therapy and so on, all of these treatments have a certain degree of alleviation of the disease, and the use of drugs should follow the doctor’s instructions. alk-d5f3 refers to the alteration of d5f3 gene in ALK fusion gene. 1. Surgery: it is applicable to the tumor that has not invaded the mediastinum, heart, large blood vessels, trachea, laryngeal reentry nerve, esophagus, vertebrae and so on, and the tumor does not have regional lymph node metastasis or the tumor has metastasis to the ipsilateral peribronchial lymph nodes, ipsilateral hilar lymph nodes, and intrapulmonary lymph nodes, but the diameter is smaller than or equal to 7 cm. Surgery is preferred to lobectomy plus lymph node dissection. 2. Drug therapy: applicable to patients with advanced and recurrent non-small cell carcinoma. For example, carboplatin plus paclitaxel combination chemotherapy is used. 3. Targeted therapy: ALK rearrangement positivity can be used as the target of targeted drugs such as erlotinib. 4. Radiation therapy: it is applicable to locally advanced patients or early patients who cannot tolerate surgery and patients with local recurrence, often combined with chemotherapy. 5. Interventional therapy: including bronchial artery perfusion chemotherapy, transbronchoscopic endoluminal chemotherapy and ultrasound-guided interventional therapy. The treatment is based on individual differences and choose different treatment methods, it is recommended that patients go to regular hospitals in a timely manner, and actively cooperate with the doctor’s treatment.